Sinohealth Holdings Limited
中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2361)

PROFIT WARNING

This announcement is made by Sinohealth Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Hong Kong Stock Exchange (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company would like to inform the shareholders and potential investors that, based on a preliminary assessment of the Group's latest unaudited consolidated management accounts for the six months ended 30 June 2025 ("**1H2025**") and the information currently available to the Board, revenue for 1H2025 will decrease by approximately 5% to 10% as compared to approximately RMB159.5 million for the same period in 2024, and net profit attributable to shareholders of listed company for 1H2025 will decrease by approximately 36% to 46% as compared to approximately RMB41.7 million for the same period in 2024.

The board of directors (the "**Board**") of the Company is of the view that the decrease in profit was mainly due to (i) the Company's strategic business restructuring and increased investment in AI research and development; (ii) decreased government subsidies received as a result of policy changes; and (iii) increased exchange losses and reduced interest income affected by foreign exchange fluctuations and interest rate cuts.

During the 1H2025, despite the decline in profit attributable to parent holders, the Company has closely followed market developments by actively expanding its innovative in-hospital data business and has achieved new progress. It has intensified AI R&D investments to build all-scenario healthcare industrial vertical-specific intelligent agents, enhancing the sector's decision-making efficiency. Additionally, the Company has expanded market penetration of existing products to strengthen its competitive edge. At the business level, as of the date of this announcement, among the contracts signed by the Company, the delivery amount is expected to increase by nearly 10% year-on-year this year. Financially, the Company has maintained a long-term prudent strategy with ample capital reserves, providing a solid foundation for sustainable business development. The Group will continue to focus on its core business, leveraging big data and artificial intelligence to further strengthen its competitive advantages, and remains committed to creating long-term value for the healthcare industry.

As of the date of this announcement, the Company has completed the finalisation of the interim results of the Group for 1H2025. The information as set out in this announcement is the Board's preliminary assessment according to the Group's unaudited consolidated management accounts and the information currently available to the Board. Such information has neither been audited and confirmed by the Company's independent auditors nor reviewed by the audit committee of the Company and is subject to adjustments. The Company's interim results announcement for 1H2025 will be published by the end of August 2025, in compliance with the Listing Rules. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for 1H2025.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman and executive Director

Hong Kong, 23 July 2025

As of the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent Directors are Ms. Wang Danzhou, Ms. Du Yilin and Mr. Wei Bin.